Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
Date:12/10/2007

Dr. Paul Richardson presents Phase 1 results demonstrating clinical

activity of perifosine in combination with bortezomib in patients previously treated with bortezomib, and provides an update on an ongoing

Phase 2 study of perifosine in combination with dexamethasone

NEW YORK, Dec. 10 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that positive phase 1 & phase 2 data of perifosine (KRX-0401) in patients with advanced, relapsed/refractory multiple myeloma (MM) were presented on Saturday, December 8, 2007 at the 49th Annual Meeting of the American Society of Hematology. In two separate poster presentations, Dr. Paul Richardson, Clinical Director of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute (DFCI) in Boston, MA, provided the phase 1 results on the clinical activity of perifosine in combination with Bortezomib, and an update on an ongoing phase 2 study of perifosine in combination with dexamethasone.

Phase 1 Perifosine + VELCADE(R) (Vel)

Poster 324-I: A MULTICENTER PHASE 1/2 TRIAL OF PERIFOSINE (KRX-0401) + BORTEZOMIB IN RELAPSED OR RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS PREVIOUSLY TREATED WITH BORTEZOMIB: PHASE I RESULTS

Eighteen patients (median age 64 yrs) with advanced MM (83% relapsed and refractory) were enrolled in one of four cohorts. Patients had a median of 5 lines of prior therapy and 100% of patients were previously treated with at least one course of therapy on bortezomib. Perifosine was escalated from 50 to 100 mg qd while bortezomib was escalated from 1.0 to 1.3 mg/mm2. No dose- limiting toxicity and no grade 3 peripheral neuropathy were reported. Toxicities were generally well
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015 ... the addition of the "Surgical/Operating Microscopes Market ... to 2020" report to their offering. ... surgical microscopes market is poised to reach $806.6 ... at a CAGR of 12.3% from 2015 to ...
(Date:5/29/2015)... Lilly and Company (NYSE: LLY ) and AstraZeneca ... entered into a clinical trial collaboration to evaluate the ... checkpoint inhibitor, MEDI4736, in combination with CYRAMZA ® ... planned study will assess the combination as a treatment ... Phase I study is expected to establish the safety ...
(Date:5/28/2015)... , May 28, 2015 Zimmer Holdings, ... it has finalized agreements with buyers to divest in ... Unicompartmental High-Flex Knee System assets, Biomet Discovery® Elbow System ... are in furtherance of Zimmer,s pending acquisition of Biomet, ... Zimmer continues to work constructively with the Bureau of ...
Breaking Medicine Technology:Surgical/Operating Microscopes Market by Application & End User - Global Forecast to 2020 for the $806 Million Industry 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 2Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 3Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 4Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 5Zimmer Announces Agreements in Furtherance of Pending Biomet Merger 6
... 4, 2011 Volcano Corporation (NASDAQ: VOLC ... diagnosis and therapy guidance tools designed to enhance the ... that it will be participating in the Bank of ... 11. The presentation by Scott Huennekens, president ...
... One Medical, Inc. ("China Sky One Medical" or "the Company") ... company in the People,s Republic of China ("PRC"), today announced ... Eastern Time (ET) on Thursday, May 12, 2011, to discuss ... Company,s quarterly report will be filed with the SEC on ...
Cached Medicine Technology:China Sky One Medical Announces Conference Call to Discuss First Quarter 2011 Results 2
(Date:5/29/2015)... As spring has sprung and summer approaches, ... increased in popularity as people finish plans for pool ... While a perennial favorite, the early Memorial Day ... weeks earlier than usual. , Similar to previous years, ... to prefer the Patio series rooms which are available ...
(Date:5/29/2015)... 2015 Healthpointe is excited to announce ... (JFT) at their clinics in Orange County. The Supartz ... assists in diminishing pain for patients with osteoarthritis, and ... and Dr. Neil Katz of Healthpointe. Supartz is an ... known as hyaluronic acid) a natural substance found in ...
(Date:5/29/2015)... 29, 2015 The report ... provides comprehensive information on the therapeutic development ... pipelines by identifying new targets and MOAs ... report on H1 2015 pipeline review of ... and 13 figures, spread across 47 pages ...
(Date:5/29/2015)... 29, 2015 Health DataPalooza is a ... to discuss and foster the most effective and innovative ... The Conference is hosted by the Health Data Consortium, ... organizations to promote and develop the use of open ... focused groups to narrow in on how to actually ...
(Date:5/29/2015)... 2015 Recently, renowned facelift specialist ... facelift surgery before the 46th National Congress of Plastic ... his presentation, Dr. Rohrich, a Dallas plastic surgeon ... Plastic Surgery at UT Southwestern Medical Center, discussed the ... they relate to obtaining long term results. , Based ...
Breaking Medicine News(10 mins):Health News:As Summer Approaches, Finnleo Notes Increased Interest in Patio and Metro Outdoor Saunas 2Health News:Healthpointe is Now Offering Supartz Joint Fluid Therapy at their Anaheim Clinic and La Mirada Clinic. 2Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Axillary Hyperhidrosis Therapeutic Assessment Pipeline Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:RowdMap, Inc. Speaks on Government Health Data and Applications for Transparency, No Value Care, and Pay-for-Value Risk Arrangements at Health Datapalooza 2Health News:RowdMap, Inc. Speaks on Government Health Data and Applications for Transparency, No Value Care, and Pay-for-Value Risk Arrangements at Health Datapalooza 3Health News:Dr. Rod J. Rohrich Speaks on Longevity in Facelifts and Facial Rejuvenation 2Health News:Dr. Rod J. Rohrich Speaks on Longevity in Facelifts and Facial Rejuvenation 3
... by clinicians at the National Heart and Lung Institute, ... a novel anti-neutrophilic effect among patients with mild asthma. ... about the effects of long-acting beta2-adrenergic receptor agonists, such ... between the ages// of 18 and 55, with mild ...
... muscle wasting condition which is a serious problem in people ... the bowel, liver, lungs and heart. A recent study has ... found in fruit flies, where it is involved in muscle ... humans. ,Researchers have been studying the function of the ...
... study by researchers of Johns Hopkins University School of Medicine ... American Medical Association suggested that obesity has a marked effect ... that the risk of increased years of life lost(YLL) was ... from various National Health// and Nutrition Examination surveys. The data ...
... have found from a recent study that there is ... one cigarette in both chronic and non-smokers. The researchers ... artery properties in 185 healthy young smokers and non-smokers ... with 41 chronic smokers with their age, height, weight ...
... of Nature Biotechnology outlines a new method developed ... required for the production of industrial molecules produced ... company's ability to improve the properties// of microbial ... new technology enables the illumination of the best ...
... A new policy by the Government of India will now ... practice in India, through a screening test that will be ... of The Ministry of Health and Family Welfare). The purpose ... the Medical Council// of India or any State Medical Council ...
Cached Medicine News:
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
The APR Hip System offers a complete line of stems to precisely match patients' anatomic needs and address surgeon preferences....
Simple straight stem design for the low-demand patient....
Medicine Products: